Drugs / GSK2881078
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02567773 | Sep 2015 → Dec 2016 | hypoproteinemia, hypercatabolic | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02045940 | Jan 2014 → Mar 2015 | hypoproteinemia, hypercatabolic | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03359473 | Feb 2018 → Nov 2019 | — | GlaxoSmithKline | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2881078 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03359473 ↗ |
| Modality | Other / unclassified | “Selective Androgen Receptor Modulator (SARM)” NCT02045940 ↗ |
| Route | Oral | “Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg” NCT02045940 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL3545174 ↗ |